Overview

Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers

Status:
Completed
Trial end date:
2019-10-19
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to compare in healthy subjects, the GI tolerability of bioequivalent doses of Bafiertam™(monomethyl fumarate) and its pro-drug Tecfidera® (dimethyl fumarate). Secondary objective of this study is to compare the safety and tolerability of Bafiertam™ and Tecfidera® when administered orally following bioequivalent dose regimens in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Banner Life Sciences LLC
Treatments:
Dimethyl Fumarate